Timothy P. Coughlin

Chief Financial Officer, Neurocrine Biosciences.

Companies

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

As of each latest filing. The line shows shares held over time.

Jun 12, 2026Sold 10,000 shares at $50.07 of Travere Therapeutics, Inc.⁷
Jun 12, 2026Exercised options 10,000 shares at $26.52 of Travere Therapeutics, Inc.⁷
Jun 9, 2026Granted 8,000 shares of VIR Biotechnology¹²
Jun 9, 2026Granted 8,000 shares of VIR Biotechnology¹²
Jun 3, 2026Shares withheld for tax 12,600 shares at $3.08 of ADC Therapeutics SA⁹
Jun 1, 2026Granted 45,000 shares of ADC Therapeutics SA⁹
May 19, 2026Granted 4,000 shares of Travere Therapeutics, Inc.¹³
May 15, 2026Sold 3,250 shares at $43.49 of Travere Therapeutics, Inc.¹⁴
Oct 31, 2025Sold 18,000 shares at $35.03 of Travere Therapeutics, Inc.¹⁵
Oct 31, 2025Exercised options 10,000 shares at $17.44 of Travere Therapeutics, Inc.¹⁵
Oct 31, 2025Exercised options 8,000 shares at $16.33 of Travere Therapeutics, Inc.¹⁵
Jun 3, 2025Granted 40,000 shares of ADC Therapeutics SA¹⁶
May 15, 2025Granted 6,500 shares of Travere Therapeutics, Inc.¹⁷
May 30, 2024Bought 50,000 shares at $1.75 of aTyr Pharma¹⁰
May 8, 2024Granted 6,500 shares of Travere Therapeutics, Inc.¹⁸
May 17, 2023Gift 6,000 shares of aTyr Pharma¹⁹
May 17, 2023Gift 6,000 shares of aTyr Pharma¹⁹
May 17, 2023Granted 4,500 shares of Travere Therapeutics, Inc.²⁰
Apr 26, 2023Exercised options 6,000 shares of aTyr Pharma²¹
Jun 9, 2022Granted 8,650 shares of Fate Therapeutics⁸
Jun 3, 2022Sold 1,439 shares at $22.81 of Fate Therapeutics²²
May 11, 2022Granted 3,000 shares of Travere Therapeutics, Inc.²³

The numbers on this page point here. Each one links to the record it came from.